Hypertonic saline ameliorates cerebral edema associated with experimental brain tumor

Thomas J K Toung, Betty Tyler, Henry Brem, Richard J. Traystman, Patricia D. Hurn, Anish Bhardwaj

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Cerebral edema commonly accompanies brain tumors and frequently leads to lethal intracranial compartmental shifts and elevated intracranial pressure. Therapeutic modalities for tumor-associated cerebral edema include diuretics, osmotherapy, and corticosteroids. Recently, hypertonic saline (HS) has received attention as an osmotic agent in the treatment of cerebral edema from diverse causes. The effects of continuous HS infusion in brain tumor-associated edema have not been previously reported. Therefore, we tested the hypothesis that HS given as a continuous intravenous infusion ameliorates tumor-associated edema in a rat model of brain tumor. 9L gliosarcoma, propagated as a solid flank tumor, was implanted intracranially over the left hemisphere in adult female Fischer 344 rats (180-220 g). On day 11 after implantation, rats were divided in a blinded, randomized fashion into groups that received no treatment or continuous infusion of 0.9% saline (NS) (0.3 mL/h) and in a subsequent series that included NS + intravenous furosemide 2.5 mg/kg every six hours, NS + intravenous mannitol 2.5 g/kg every six hours, or continuous infusion 7.5% HS (chloride: acetate 50:50) (0.3 mL/h). Hemispheric water content ipsilateral (IH) and contralateral to tumor implantation was determined at day 13 by wet-to-dry weight ratio after 48 hours of therapy. Ipsilateral hemispheric water content (mean ± SEM) was significantly increased in rats with intracranial tumor on day 11 (80. 3 ± 0.5 %) (n = 7) and day 13 (81.4 ± 0.3 %) (n = 10), as compared to naive weight-matched rats without tumor implant (79.3 ± 0.1%) (n = 13) (P < .05). After 48 hours of treatment, IH water content was attenuated with continuous HS (n = 15) (79.3 ± 0.2%), mannitol (n = 14) (80.1 ± 0.2%), and furosemide (n = 15) (79.9 ± 0.2%) as compared to NS (n = 7) (80.8 ± 0.5%). Continuous HS infusion attenuated cerebral edema in the affected hemisphere as well as the contralateral noninjured hemisphere to a larger extent than was observed with furosemide or mannitol. These findings suggest a potential new treatment strategy for tumorassociated cerebral edema.

Original languageEnglish (US)
Pages (from-to)187-193
Number of pages7
JournalJournal of Neurosurgical Anesthesiology
Volume14
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Brain Edema
Brain Neoplasms
Furosemide
Mannitol
Neoplasms
Edema
Gliosarcoma
Weights and Measures
Intracranial Hypertension
Water
Water Purification
Inbred F344 Rats
Therapeutics
Diuretics
Intravenous Infusions
Chlorides
Adrenal Cortex Hormones
Acetates

Keywords

  • Edema
  • Furosemide
  • Hypertonic saline
  • Mannitol
  • Osmotic
  • Tumor

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Cite this

Hypertonic saline ameliorates cerebral edema associated with experimental brain tumor. / Toung, Thomas J K; Tyler, Betty; Brem, Henry; Traystman, Richard J.; Hurn, Patricia D.; Bhardwaj, Anish.

In: Journal of Neurosurgical Anesthesiology, Vol. 14, No. 3, 2002, p. 187-193.

Research output: Contribution to journalArticle

Toung, Thomas J K ; Tyler, Betty ; Brem, Henry ; Traystman, Richard J. ; Hurn, Patricia D. ; Bhardwaj, Anish. / Hypertonic saline ameliorates cerebral edema associated with experimental brain tumor. In: Journal of Neurosurgical Anesthesiology. 2002 ; Vol. 14, No. 3. pp. 187-193.
@article{8946f822b8f04b76bed7c01b0393abd2,
title = "Hypertonic saline ameliorates cerebral edema associated with experimental brain tumor",
abstract = "Cerebral edema commonly accompanies brain tumors and frequently leads to lethal intracranial compartmental shifts and elevated intracranial pressure. Therapeutic modalities for tumor-associated cerebral edema include diuretics, osmotherapy, and corticosteroids. Recently, hypertonic saline (HS) has received attention as an osmotic agent in the treatment of cerebral edema from diverse causes. The effects of continuous HS infusion in brain tumor-associated edema have not been previously reported. Therefore, we tested the hypothesis that HS given as a continuous intravenous infusion ameliorates tumor-associated edema in a rat model of brain tumor. 9L gliosarcoma, propagated as a solid flank tumor, was implanted intracranially over the left hemisphere in adult female Fischer 344 rats (180-220 g). On day 11 after implantation, rats were divided in a blinded, randomized fashion into groups that received no treatment or continuous infusion of 0.9{\%} saline (NS) (0.3 mL/h) and in a subsequent series that included NS + intravenous furosemide 2.5 mg/kg every six hours, NS + intravenous mannitol 2.5 g/kg every six hours, or continuous infusion 7.5{\%} HS (chloride: acetate 50:50) (0.3 mL/h). Hemispheric water content ipsilateral (IH) and contralateral to tumor implantation was determined at day 13 by wet-to-dry weight ratio after 48 hours of therapy. Ipsilateral hemispheric water content (mean ± SEM) was significantly increased in rats with intracranial tumor on day 11 (80. 3 ± 0.5 {\%}) (n = 7) and day 13 (81.4 ± 0.3 {\%}) (n = 10), as compared to naive weight-matched rats without tumor implant (79.3 ± 0.1{\%}) (n = 13) (P < .05). After 48 hours of treatment, IH water content was attenuated with continuous HS (n = 15) (79.3 ± 0.2{\%}), mannitol (n = 14) (80.1 ± 0.2{\%}), and furosemide (n = 15) (79.9 ± 0.2{\%}) as compared to NS (n = 7) (80.8 ± 0.5{\%}). Continuous HS infusion attenuated cerebral edema in the affected hemisphere as well as the contralateral noninjured hemisphere to a larger extent than was observed with furosemide or mannitol. These findings suggest a potential new treatment strategy for tumorassociated cerebral edema.",
keywords = "Edema, Furosemide, Hypertonic saline, Mannitol, Osmotic, Tumor",
author = "Toung, {Thomas J K} and Betty Tyler and Henry Brem and Traystman, {Richard J.} and Hurn, {Patricia D.} and Anish Bhardwaj",
year = "2002",
doi = "10.1097/00008506-200207000-00003",
language = "English (US)",
volume = "14",
pages = "187--193",
journal = "Journal of Neurosurgical Anesthesiology",
issn = "0898-4921",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Hypertonic saline ameliorates cerebral edema associated with experimental brain tumor

AU - Toung, Thomas J K

AU - Tyler, Betty

AU - Brem, Henry

AU - Traystman, Richard J.

AU - Hurn, Patricia D.

AU - Bhardwaj, Anish

PY - 2002

Y1 - 2002

N2 - Cerebral edema commonly accompanies brain tumors and frequently leads to lethal intracranial compartmental shifts and elevated intracranial pressure. Therapeutic modalities for tumor-associated cerebral edema include diuretics, osmotherapy, and corticosteroids. Recently, hypertonic saline (HS) has received attention as an osmotic agent in the treatment of cerebral edema from diverse causes. The effects of continuous HS infusion in brain tumor-associated edema have not been previously reported. Therefore, we tested the hypothesis that HS given as a continuous intravenous infusion ameliorates tumor-associated edema in a rat model of brain tumor. 9L gliosarcoma, propagated as a solid flank tumor, was implanted intracranially over the left hemisphere in adult female Fischer 344 rats (180-220 g). On day 11 after implantation, rats were divided in a blinded, randomized fashion into groups that received no treatment or continuous infusion of 0.9% saline (NS) (0.3 mL/h) and in a subsequent series that included NS + intravenous furosemide 2.5 mg/kg every six hours, NS + intravenous mannitol 2.5 g/kg every six hours, or continuous infusion 7.5% HS (chloride: acetate 50:50) (0.3 mL/h). Hemispheric water content ipsilateral (IH) and contralateral to tumor implantation was determined at day 13 by wet-to-dry weight ratio after 48 hours of therapy. Ipsilateral hemispheric water content (mean ± SEM) was significantly increased in rats with intracranial tumor on day 11 (80. 3 ± 0.5 %) (n = 7) and day 13 (81.4 ± 0.3 %) (n = 10), as compared to naive weight-matched rats without tumor implant (79.3 ± 0.1%) (n = 13) (P < .05). After 48 hours of treatment, IH water content was attenuated with continuous HS (n = 15) (79.3 ± 0.2%), mannitol (n = 14) (80.1 ± 0.2%), and furosemide (n = 15) (79.9 ± 0.2%) as compared to NS (n = 7) (80.8 ± 0.5%). Continuous HS infusion attenuated cerebral edema in the affected hemisphere as well as the contralateral noninjured hemisphere to a larger extent than was observed with furosemide or mannitol. These findings suggest a potential new treatment strategy for tumorassociated cerebral edema.

AB - Cerebral edema commonly accompanies brain tumors and frequently leads to lethal intracranial compartmental shifts and elevated intracranial pressure. Therapeutic modalities for tumor-associated cerebral edema include diuretics, osmotherapy, and corticosteroids. Recently, hypertonic saline (HS) has received attention as an osmotic agent in the treatment of cerebral edema from diverse causes. The effects of continuous HS infusion in brain tumor-associated edema have not been previously reported. Therefore, we tested the hypothesis that HS given as a continuous intravenous infusion ameliorates tumor-associated edema in a rat model of brain tumor. 9L gliosarcoma, propagated as a solid flank tumor, was implanted intracranially over the left hemisphere in adult female Fischer 344 rats (180-220 g). On day 11 after implantation, rats were divided in a blinded, randomized fashion into groups that received no treatment or continuous infusion of 0.9% saline (NS) (0.3 mL/h) and in a subsequent series that included NS + intravenous furosemide 2.5 mg/kg every six hours, NS + intravenous mannitol 2.5 g/kg every six hours, or continuous infusion 7.5% HS (chloride: acetate 50:50) (0.3 mL/h). Hemispheric water content ipsilateral (IH) and contralateral to tumor implantation was determined at day 13 by wet-to-dry weight ratio after 48 hours of therapy. Ipsilateral hemispheric water content (mean ± SEM) was significantly increased in rats with intracranial tumor on day 11 (80. 3 ± 0.5 %) (n = 7) and day 13 (81.4 ± 0.3 %) (n = 10), as compared to naive weight-matched rats without tumor implant (79.3 ± 0.1%) (n = 13) (P < .05). After 48 hours of treatment, IH water content was attenuated with continuous HS (n = 15) (79.3 ± 0.2%), mannitol (n = 14) (80.1 ± 0.2%), and furosemide (n = 15) (79.9 ± 0.2%) as compared to NS (n = 7) (80.8 ± 0.5%). Continuous HS infusion attenuated cerebral edema in the affected hemisphere as well as the contralateral noninjured hemisphere to a larger extent than was observed with furosemide or mannitol. These findings suggest a potential new treatment strategy for tumorassociated cerebral edema.

KW - Edema

KW - Furosemide

KW - Hypertonic saline

KW - Mannitol

KW - Osmotic

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=0036020236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036020236&partnerID=8YFLogxK

U2 - 10.1097/00008506-200207000-00003

DO - 10.1097/00008506-200207000-00003

M3 - Article

C2 - 12172290

AN - SCOPUS:0036020236

VL - 14

SP - 187

EP - 193

JO - Journal of Neurosurgical Anesthesiology

JF - Journal of Neurosurgical Anesthesiology

SN - 0898-4921

IS - 3

ER -